Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Silvia Salvatori, Benedetto Neri, Irene Marafini, Mattia Brigida & Giovanni Monteleone. (2023) Emerging oral drug options for ulcerative colitis. Expert Opinion on Emerging Drugs 0:0, pages 1-11.
Read now
Read now
Yafei Liu & Fei Liao. (2023) Vaccination therapy for inflammatory bowel disease. Human Vaccines & Immunotherapeutics 19:2.
Read now
Read now
Gabrio Bassotti, Alessandro Fruganti, Giovanni Maconi, Pierfrancesco Marconi & Katia Fettucciari. (2021) Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease May be Favoured by the Effects of Proinflammatory Cytokines on the Enteroglial Network. Journal of Inflammation Research 14, pages 7443-7453.
Read now
Read now
Lieven Pouillon, Peter Bossuyt, Joke Vanderstukken, David Moulin, Patrick Netter, Silvio Danese, Jean-Yves Jouzeau, Damien Loeuille & Laurent Peyrin-Biroulet. (2017) Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Review of Clinical Pharmacology 10:12, pages 1363-1374.
Read now
Read now
Articles from other publishers (32)
Fenna M Jansen, Reinier C A van Linschoten, Wietske Kievit, Lisa J T Smits, Renske W M Pauwels, Dirk J de Jong, Annemarie C de Vries, Paul J Boekema, Rachel L West, Alexander G L Bodelier, Ingrid A M Gisbertz, Frank H J Wolfhagen, Tessa E H Römkens, Maurice W M D Lutgens, Adriaan A van Bodegraven, Bas Oldenburg, Marieke J Pierik, Maurice G V M Russel, Nanne K de Boer, Rosalie C Mallant-Hent, Pieter C J ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, Frank Hoentjen, C Janneke van der Woude, Desirée van Noord, Jildou Hoekstra, Johannes T Kamphuis, Moniek H P Gorter & Aura A J van Esch. (2023) Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial. Journal of Crohn's and Colitis 17:11, pages 1771-1780.
Crossref
Crossref
Zhejie Chen, Yi Chen, Wei Hao, Mingju Shui, Jinming Zhang, Hefeng Zhou, Chen Zhang, Yitao Wang & Shengpeng Wang. (2023) Oral Delivery of Transformable Bilirubin Self‐Assembled System for Targeted Therapy of Colitis. Advanced Healthcare Materials 12:26.
Crossref
Crossref
Melek Simsek, Femke Schepers, Sigal Kaplan, Dirk van Asseldonk, Petra van Boeckel, Paul Boekema, Gerard Dijkstra, Herma Fidder, Ingrid Gisbertz, Frank Hoentjen, Bindia Jharap, Frank Kubben, Marleen de Leest, Maarten Meijssen, Ana Petrak, Else van de Poel, Maurice Russel, Adriaan A van Bodegraven, Chris J J Mulder & Nanne de Boer. (2023) Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study. Journal of Crohn's and Colitis 17:6, pages 933-942.
Crossref
Crossref
Fernanda Serafim Nakutis, Iêda Nishitokukado, Fabiana Maria dos Santos, Carmen Lucia Ortiz-Agostinho, Daniel Teixeira de Alencar, Cassiana Ganem Achtschin, Valeria Sutti Nunes, André Zonetti Arruda Leite & Aytan Miranda Sipahi. (2023) Evaluation of oxidative stress in an experimental model of Crohn's disease treated with hyperbaric oxygen therapy. Clinics 78, pages 100305.
Crossref
Crossref
Dipen Patel, Stephan Martin, Michelle Luo, Lyann Ursos, Richard A Lirio, Pravin Kamble & Song Wang. (2022) Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review. Crohn's & Colitis 360 4:3.
Crossref
Crossref
Kathrin Perrig, Niklas Krupka, Sebastian Bruno Ulrich Jordi, Jean-Benoît Rossel, Luc Biedermann, Thomas Greuter, Philipp Schreiner, Stephan R. Vavricka, Pascal Juillerat, Emanuel Burri, Dorothee Zimmermann, Michel H. Maillard, Michael Christian Sulz, Stephan Brand, Gerhard Rogler & Benjamin Misselwitz. (2022) Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therapeutic Advances in Gastroenterology 15, pages 175628482210741.
Crossref
Crossref
Samane Tavassoli, Iman Shahabinasab, Alireza Norouzi, Taghi Amiriani, Nafiseh Abdolahi, Somayeh Livani, Seyed Farzam Mirkamali, Honey Sadat Mirkarimi, Fazel Isapanah Amlashi & Sima Besharat. (2021) From bowel inflammation to the bone and joints: musculoskeletal examination in inflammatory bowel disease (IBD). BMC Musculoskeletal Disorders 22:1.
Crossref
Crossref
Amanda E. Starr, Shelley A. Deeke, Zhibin Ning, Joseph de Nanassy, Ruth Singleton, Eric I. Benchimol, David R. Mack, Alain Stintzi & Daniel Figeys. (2021) Associations between Cellular Energy and Pediatric Inflammatory Bowel Disease Patient Response to Treatment. Journal of Proteome Research 20:9, pages 4393-4404.
Crossref
Crossref
M Valter, S Verstockt, J A Finalet Ferreiro & I Cleynen. (2021) Extracellular Vesicles in Inflammatory Bowel Disease: Small Particles, Big Players. Journal of Crohn's and Colitis 15:3, pages 499-510.
Crossref
Crossref
Silje W Syversen, Guro L Goll, Kristin K Jørgensen, Inge C Olsen, Øystein Sandanger, Johanna E Gehin, David J Warren, Joseph Sexton, Cato Mørk, Jørgen Jahnsen, Tore K Kvien, Nils Bolstad & Espen A Haavardsholm. (2020) Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials 21:1.
Crossref
Crossref
J.A. Kroes, S.W. Zielhuis, E.N. van Roon & A. ten Brinke. (2020) Prediction of response to biological treatment with monoclonal antibodies in severe asthma. Biochemical Pharmacology 179, pages 113978.
Crossref
Crossref
Pavine L C Lefevre & Niels Vande Casteele. (2020) Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 14:Supplement_2, pages S725-S736.
Crossref
Crossref
Jiaxin Zhang, Yuge Zhao, Tianling Hou, Hairong Zeng, Dipika Kalambhe, Bing Wang, Xiaoyan Shen & Yongzhuo Huang. (2020) Macrophage-based nanotherapeutic strategies in ulcerative colitis. Journal of Controlled Release 320, pages 363-380.
Crossref
Crossref
Michelle Heib, Stefan Rose-John & Dieter Adam. 2020. Cell Death Regulation In Health And Disease - Part C. Cell Death Regulation In Health And Disease - Part C
83
152
.
Lieven Pouillon, Séverine Vermeire & Peter Bossuyt. (2019) Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. BMC Medicine 17:1.
Crossref
Crossref
Jean Lawton, Hamza Achit, Lieven Pouillon, Emmanuelle Boschetti, Béatrice Demore, Thierry Matton, Charlène Tournier, Martin Prodel, Laurent Peyrin-Biroulet & Francis Guillemin. (2019) Cost‐of‐illness of inflammatory bowel disease patients treated with anti‐tumour necrosis factor: A French large single‐centre experience. United European Gastroenterology Journal 7:7, pages 908-913.
Crossref
Crossref
Marjorie C. Argollo, Mariangela Allocca, Federica Furfaro, Laurent Peyrin-Biroulet & Silvio Danese. (2019) Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. Current Pharmaceutical Design 25:1, pages 25-31.
Crossref
Crossref
Lieven Pouillon, Cédric Baumann, Hélène Rousseau, Myriam Choukour, Charlotte Andrianjafy, Silvio Danese & Laurent Peyrin-Biroulet. (2019) Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. Inflammatory Bowel Diseases 25:5, pages 945-954.
Crossref
Crossref
Laurent Peyrin-Biroulet, Silvio Danese, Marjorie Argollo, Lieven Pouillon, Spyros Peppas, Marien Gonzalez-Lorenzo, Theodore Lytras & Stefanos Bonovas. (2019) Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 17:5, pages 838-846.e2.
Crossref
Crossref
M. Body-Malapel, M. Djouina, C. Waxin, A. Langlois, C. Gower-Rousseau, P. Zerbib, A.-M. Schmidt, P. Desreumaux, E. Boulanger & C. Vignal. (2019) The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for Inflammatory Bowel Diseases. Mucosal Immunology 12:2, pages 468-478.
Crossref
Crossref
Lieven Pouillon, Anne Lamoureux, Guillaume Pineton de Chambrun, Lucine Vuitton, Benjamin Pariente, Camille Zallot, Gaspard Dufour, Mathurin Fumery, Cédric Baumann, Aurélien Amiot, Stéphane Nancey, Hélène Rousseau & Laurent Peyrin-Biroulet. (2019) Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease—A multicenter, retrospective, observational study. Digestive and Liver Disease 51:2, pages 236-241.
Crossref
Crossref
Vincenzo Villanacci, Moris Cadei, Francesco Lanzarotto, Chiara Ricci, Elisabetta Antonelli, Rosanna Cannatelli, Tiziana Gulotta, Lucia Fontana, Valentina Pasquali, Sandra Sigala, Tiziana Salviato, Riccardo Nascimbeni & Gabrio Bassotti. (2019) Localization of TNF alpha in ileocolonic biopsies of patients with inflammatory bowel disease. Annals of Diagnostic Pathology 38, pages 20-25.
Crossref
Crossref
Peter Bossuyt, Filip Baert, Francois D’Heygere, Antoine Nakad, Catherine Reenaers, Fernand Fontaine, Denis Franchimont, Olivier Dewit, Philippe Van Hootegem, Stijn Vanden Branden, Guy Lambrecht, Marc Ferrante, Pieter Hindryckx, Elisabeth Macken, Philip Caenepeel, Anne Vijverman, Nicolas de Suray, Joris Dutré, Edouard Louis & Jean-Louis Coenegracths. (2019) Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. Inflammatory Bowel Diseases 25:1, pages 156-162.
Crossref
Crossref
Elisabetta Antonelli, Vincenzo Villanacci & Gabrio Bassotti. (2018) Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World Journal of Gastroenterology 24:47, pages 5322-5330.
Crossref
Crossref
Bjoern Titz, Raffaella Gadaleta, Giuseppe Lo Sasso, Ashraf Elamin, Kim Ekroos, Nikolai Ivanov, Manuel Peitsch & Julia Hoeng. (2018) Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification. International Journal of Molecular Sciences 19:9, pages 2775.
Crossref
Crossref
Nicholas Carman, David R. Mack & Eric I. Benchimol. (2018) Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports 20:5.
Crossref
Crossref
Lieven Pouillon, Johan Van Stappen, Peter Bossuyt, Silvio Danese & Laurent Peyrin-Biroulet. (2018) Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. Best Practice & Research Clinical Gastroenterology 32-33, pages 17-25.
Crossref
Crossref
Elizabeth A. Spencer & Marla C. Dubinsky. (2017) Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Pediatric Clinics of North America 64:6, pages 1309-1326.
Crossref
Crossref
Marjorie Argollo, Gionata Fiorino, Pieter Hindryckx, Laurent Peyrin-Biroulet & Silvio Danese. (2017) Novel therapeutic targets for inflammatory bowel disease. Journal of Autoimmunity 85, pages 103-116.
Crossref
Crossref
Pawin Pongkorpsakol, Aekkacha Moonwiriyakit & Chatchai Muanprasat. (2017) Fatty acid and mineral receptors as drug targets for gastrointestinal disorders. Future Medicinal Chemistry 9:3, pages 315-334.
Crossref
Crossref
Pieter Hindryckx, Gregor Novak, Niels Vande Casteele, Reena Khanna, Debby Laukens, Jairath Vipul & Brian G. Feagan. (2017) Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. Drugs 77:4, pages 363-377.
Crossref
Crossref
Pablo Olivera, Silvio Danese & Laurent Peyrin-Biroulet. (2017) Next generation of small molecules in inflammatory bowel disease. Gut 66:2, pages 199-209.
Crossref
Crossref